Tech Company Financing Transactions
N30 Pharmaceuticals Funding Round
Deerfield Capital, Jennison Associates and RA Capital joined a $20 million funding round for N30 Pharmaceuticals. The round closed on 11/20/2014.
Transaction Overview
Company Name
Announced On
11/20/2014
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds from the financing will primarily be used to advance the Company's clinical trial program for N91115, a novel inhibitor S-nitrosoglutathione reluctase (GSNOR).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3122 Sterling Cir. 200
Boulder, CO 80301
USA
Boulder, CO 80301
USA
Phone
Website
Email Address
Overview
N30 Pharmaceuticals, LLC is developing s-nitrosothiol therapies for important unmet needs in respiratory diseases. N30's strategy focuses on administration of GSNO to the human airway, and development of small molecule inhibitors of GSNO reductase.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jon Congleton
Chief Financial Officer
Tom Sokolowski
VP - R & D
Sherif Gabriel
VP - Regulatory Affairs
Janice Troha
Browse more venture capital transactions:
Prev: 11/20/2014: Flashback Technologies venture capital transaction
Next: 11/20/2014: Cue venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs